Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Looking for a targeted approach to weight loss
With the recent approval of tirzepatide [42, 43] as a dual-hormone-receptor agonist that targets both GLP-1R and GIPR, investigating the potential of simultaneously targeting the GIP receptor with GLP-1 and GCG receptors to develop a triple-hormone-receptor agonist holds immense promise for next-generation peptide-based therapeutics
Hlsmann, I
To better understand what those effects can look like, read our tirzepatide side effects guide
US$ 20.70
US$ 21.36
US$ 25.67
